• Je něco špatně v tomto záznamu ?

Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy

RA. Diotti, N. Mancini, N. Clementi, G. Sautto, GJ. Moreno, E. Criscuolo, F. Cappelletti, P. Man, E. Forest, L. Remy, S. Giannecchini, M. Clementi, R. Burioni,

. 2014 ; 108 (-) : 94-103.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014236

JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54% of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014236
003      
CZ-PrNML
005      
20150423111449.0
007      
ta
008      
150420s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.antiviral.2014.05.017 $2 doi
035    __
$a (PubMed)24909571
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Diotti, Roberta Antonia $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
245    10
$a Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy / $c RA. Diotti, N. Mancini, N. Clementi, G. Sautto, GJ. Moreno, E. Criscuolo, F. Cappelletti, P. Man, E. Forest, L. Remy, S. Giannecchini, M. Clementi, R. Burioni,
520    9_
$a JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54% of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.
650    _2
$a monoklonální protilátky $x genetika $x imunologie $7 D000911
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a neutralizující protilátky $x genetika $x imunologie $7 D057134
650    _2
$a protilátky virové $x genetika $x imunologie $7 D000914
650    _2
$a virové plášťové proteiny $x antagonisté a inhibitory $x imunologie $7 D036022
650    _2
$a klonování DNA $7 D003001
650    _2
$a epitopy $x genetika $x imunologie $7 D000939
650    _2
$a lidé $7 D006801
650    _2
$a progresivní multifokální leukoencefalopatie $x imunologie $x prevence a kontrola $7 D007968
650    _2
$a roztroušená skleróza $x terapie $7 D009103
650    _2
$a neutralizační testy $x metody $7 D009500
650    _2
$a Polyomavirus $x imunologie $7 D011120
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mancini, Nicasio $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy. Electronic address: mancini.nicasio@hsr.it.
700    1_
$a Clementi, Nicola $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
700    1_
$a Sautto, Giuseppe $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
700    1_
$a Moreno, Guisella Janett $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
700    1_
$a Criscuolo, Elena $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
700    1_
$a Cappelletti, Francesca $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
700    1_
$a Man, Petr $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Department of Biochemistry, Faculty of Sciences, Charles University, Prague, Czech Republic.
700    1_
$a Forest, Eric $u Institut de Biologie Structurale, CEA, CNRS, UJF, Grenoble, France.
700    1_
$a Remy, Louise $u Institut de Biologie Structurale, CEA, CNRS, UJF, Grenoble, France.
700    1_
$a Giannecchini, Simone $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
700    1_
$a Clementi, Massimo $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy.
700    1_
$a Burioni, Roberto $u Laboratorio di Microbiologia e Virologia, Università "Vita-Salute" San Raffaele, Milan, Italy. Electronic address: burioni.roberto@hsr.it.
773    0_
$w MED00000480 $t Antiviral research $x 1872-9096 $g Roč. 108, č. - (2014), s. 94-103
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24909571 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150423111749 $b ABA008
999    __
$a ok $b bmc $g 1071817 $s 897114
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 108 $c - $d 94-103 $i 1872-9096 $m Antiviral research $n Antiviral Res $x MED00000480
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace